MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/pbc.28040

Медицинская библиотека · Pediatric blood & cancer · 2019

Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia.

Finch Emily R, Smith Colton A, Yang Wenjian, Liu Yiwei, Kornegay Nancy M, Panetta John C, Crews Kristine R, Molinelli Alejandro R, Cheng Cheng, Pei Deqing, Ramsey Laura B, Karol Seth E, Inaba Hiroto, Sandlund John T, Metzger Monika, Evans William E, Jeha Sima, Pui Ching-Hon, Relling Mary V

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Glucocorticoids and asparaginase, used to treat acute lymphoblastic leukemia (ALL), can cause hypertriglyceridemia. We compared triglyceride levels, risk factors, and associated toxicities in two ALL trials at St. Jude Children's Research Hospital with identical glucocorticoid regimens, but different asparaginase formulations. In Total XV (TXV), native Escherichia coli l-asparaginase was front-line therapy versus the pegylated formulation (PEG-asparaginase) in Total XVI (TXVI).

PROCEDURE: Patients enrolled on TXV (n = 498) and TXVI (n = 598) were assigned to low-risk (LR) or standard/high-risk (SHR) treatment arms (ClinicalTrials.gov identifiers: NCT00137111 and NCT00549848). Triglycerides were measured four times and were evaluable in 925 patients (TXV: n = 362; TXVI: n = 563). The genetic contribution was assessed using a triglyceride polygenic risk score (triglyceride-PRS). Osteonecrosis, thrombosis, and pancreatitis were prospectively graded.

RESULTS

The largest increase in triglycerides occurred in TXVI SHR patients treated with dexamethasone and PEG-asparaginase (4.5-fold increase; P <1 × 10-15 ). SHR patients treated with PEG-asparaginase (TXVI) had more severe hypertriglyceridemia (>1000 mg/dL) compared to native l-asparaginase (TXV): 10.5% versus 5.5%, respectively (P = .007). At week 7, triglycerides did not increase with dexamethasone treatment alone (LR patients) but did increase with dexamethasone plus asparaginase (SHR patients). The variability in triglycerides explained by the triglyceride-PRS was highest at baseline and declined with therapy. Hypertriglyceridemia was associated with osteonecrosis (P = .0006) and thrombosis (P = .005), but not pancreatitis (P = .4).

CONCLUSION

Triglycerides were affected more by PEG-asparaginase than native l-asparaginase, by asparaginase more than dexamethasone, and by drug effects more than genetics. It is not clear whether triglycerides contribute to thrombosis and osteonecrosis or are biomarkers of the toxicities.

Для цитирования: Finch Emily R, Smith Colton A, Yang Wenjian, Liu Yiwei, Kornegay Nancy M, Panetta John C, Crews Kristine R, Molinelli Alejandro R, Cheng Cheng, Pei Deqing, Ramsey Laura B, Karol Seth E, Inaba Hiroto, Sandlund John T, Metzger Monika, Evans William E, Jeha Sima, Pui Ching-Hon, Relling Mary V. Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia.. Pediatric blood & cancer. 2019. DOI: 10.1002/pbc.28040.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.